Presentations at ASCO 2023 focus on improving outcomes for patients with TNBC and HR+/HER2- metastatic breast cancer.
Studies from ASCO 2023 revealed new potential standards of care for multiple myeloma and a first for bispecific antibody therapy.
Neoadjuvant FOLFIRINOX does not provide a survival benefit over upfront surgery in resectable pancreatic cancer, a phase 2 study suggests.
Adding nivolumab to adjuvant chemotherapy did not improve relapse-free survival in a phase 3 trial of patients with gastric/GEJ cancer.
Results of the Breast Cancer Weight Loss trial were presented at the 2023 ASCO Annual Meeting.